Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.
INTRODUCTION
Allo-SCT is one of the most controversially debated treatment modalities in multiple myeloma (MM). Early studies using myeloablative (MA) conditioning approaches suggested that allo-SCT may have curative potential in some patients, but also demonstrated prohibitively high non-relapse mortality (NRM).
1,2 As a consequence, MA allo-SCT for MM has been largely abandoned. 3 Over the last decade, a number of studies investigated up-front reduced intensity-conditioned (RIC) allo-SCT and reported substantially lower NRM rates compared with MA allo-SCT. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Whereas some of these studies reported better longterm outcomes with RIC allo-SCT compared with tandem autologous hematopoietic SCT (auto-SCT), others failed to demonstrate a benefit of up-front RIC allo-SCT. Therefore, there is widespread reluctance to offer patients' up-front allo-SCT, which is at least partly due to prolonged remissions that can be achieved following induction and/or maintenance therapy with novel agents. 14 Consolidation with auto-SCT remains a standard of care for most patients under the age of 65-70 years. 15 Once patients relapse/ progress after auto-SCT, long-term prognosis is unfavourable. The findings of several small studies suggest that RIC allo-SCT is feasible in patients who have relapsed after auto-SCT and may result in prolonged remissions. [16] [17] [18] [19] [20] [21] However, the role of RIC allo-SCT in the relapsed setting is not well defined, and factors that allow the early identification of relapsed patients who are likely to benefit from RIC allo-SCT have not been identified yet. To address this gap in knowledge, we performed a study of 413 patients reported to the European Group for Blood and Marrow Transplantation over a 10-year period who underwent RIC allo-SCT for MM relapsed after prior auto-SCT.
PATIENTS AND METHODS Patients
Patients included in this study were reported to the European Group for Blood and Marrow Transplantation for undergoing a RIC allo-SCT between 1 January 1999 and 31 December 2008. All patients had to have a diagnosis of MM and underwent at least one prior auto-SCT, but no previous allo-SCT. Patients had at least one documented progression/ relapse after an auto-SCT, and had no other SCT performed between the most recent documented relapse/progression and the RIC allo-SCT (n ¼ 633). Therefore, patients who received tandem auto-allo-SCT for relapse were not included in this study. Patients selected for the final analysis had to have the components of the conditioning regimen documented in the database (n ¼ 413). RIC allo-SCT was defined as previously described. 22 Response, relapse and disease progression were defined as previously described. 23, 24 Chronic GVHD was evaluated in patients surviving 4100 days after the RIC allo-SCT. Informed consent to data utilisation was obtained as previously described. 22 Statistical analyisis OS and PFS were calculated using the Kaplan-Meier method, while probabilities of NRM were estimated using the cumulative incidence method. OS was measured in months and defined as the time from the date of RIC allo-SCT until the date of death or last follow-up. PFS was defined as the time from RIC allo-SCT until the date of progression/death from any cause or last follow-up. NRM was defined as death due to any cause, which occurred without previous disease progression or relapse after RIC allo-SCT. Univariate comparisons were made using the log-rank test for OS and PFS, and Gray's test for NRM. 25 Variables included in univariate analysis were myeloma subtype, year of RIC-allo-SCT, age, number of previous auto-SCTs, time from the first auto-SCT to RIC-allo-SCT, stem cell source, donor type, T cell depletion, recipient/donor gender, recipient/donor CMV serostatus and remission status at RIC-allo-SCT (Supplementary Table 1 ). Variables found to be significant at the Po0.2 level for OS and PFS were entered into a proportional hazards regression analysis, while for NRM modelling by Fine and Grey 26 was utilised.
RESULTS

Patient characteristics
A total of 413 patients from 121 centres were included in the analysis. Their characteristics are shown in detail in Table 1 . Briefly, the majority of patients were male (64.2%), and median age at the time of RIC allo-SCT was 54.1 years. Median age at diagnosis was 50 years, and median time from the first auto-SCT to the RIC allo-SCT was 2.6 years. The majority of the patients had undergone one or two prior auto-SCTs, with a small proportion having undergone three or four auto-SCTs. At diagnosis, most patients had been in Durie-Salmon stage III. The majority of patients (68%) were transplanted in PR/4PR. Transplant-related characteristics Transplant-related characteristics are shown in detail in Table 2 . More than half of the stem cell donors were siblings (57.9%); over a third were unrelated (38.4%). Most transplants were sex-matched (56%), with 26.3% female-to-male and 17.7% male-to-female transplantations. Patient or donor CMV serostatus was positive (hereafter referred to as 'CMV seropositivity') in 74%, and negative for both patient and donor ('CMV seronegativity') in 26% of evaluable patients. Peripheral blood was the stem cell source in most patients (90.3%). The vast majority of conditioning regimens were fludarabinebased. Almost half (46%) of the RIC allo-SCTs were T cell depleted, most of which were in vivo depletions (40.9%) using antithymocyte globulin. GVHD prophylaxis included CsA in most patients (88.4%).
Outcomes Engraftment, GVHD and best response. Outcome data for the study population are shown in Table 3 . Engraftment failure or death before engraftment was reported for 11 patients (2.7%). Acute GVHD grades II-IV developed in 33% of all evaluable patients. Limited and extensive chronic GVHD were documented in 21.7 and 26.7% of all evaluable patients, respectively. Best responses were 4PR in 36.5%, PR in 25.1% and oPR in 15.3% of the evaluable patients (best response assessment unavailable due to death or insufficient data in 23.1%).
OS. Median OS from RIC allo-SCT for all patients was 24.7 months (95% confidence interval, 18.7-30.7; Table 3 ). In univariate analysis (Supplementary Table 1 ), patient/donor CMV serostatus, age at RIC allo-SCT, number of prior auto-SCT and remission status at RICallo-SCT were associated with OS. In multivariate analysis (Table 4) , CMV seronegativity and one (compared with X2) prior auto-SCT remained associated with better OS, with age almost reaching significance. When adjusted for both age and number of previous auto-SCTs, CMV seronegativity remained associated with better survival (P ¼ 0.014, Figure 1a ).
PFS.
Median PFS from RIC allo-SCT for all patients was 9.6 months (95% confidence interval, 7.3-11.8; Table 3 ). CMV seronegativity and patient/donor gender mismatch were associated with better PFS in both uni-and multivariate analyses (Supplementary Table 1, Table 4 and Figure 1b) .
NRM. Cumulative NRM was 10.5% at 3 months, 21.5% at 1 year and 28.4% at 3 years (Table 3) . CMV seronegativity and time from the first auto-SCT to RIC allo-SCT of o2.6 years were associated with lower NRM in uni-and multivariate analysis (Supplementary Table 1 and Table 4 ).
DISCUSSION
In this study, we identify patient and donor CMV seronegativity as a key prognostic factor for outcome of RIC allo-SCT for MM relapsed after prior auto-SCT. Patient and donor CMV seronegativity was the only factor identified that affected NRM, PFS and OS. CMV infection has long been recognised as an important cause of morbidity and mortality in recipients of allo-SCT. 27 However, previously published studies investigating allo-SCT in MM have not analysed the impact of CMV serostatus on outcome. [5] [6] [7] [8] [9] [10] [11] 22, 28, 29 Primary infection or re-activation can occur in CMV-seropositive recipients and recipients of grafts from seropositive donors. The availability of sensitive monitoring methods for the detection of CMV reactivation, combined with pre-emptive anti-CMV therapy, Abbreviations: Auto-SCT ¼ autologous SCT; CI ¼ confidence interval; NRM ¼ non-relapse mortality; RIC allo-SCT ¼ reduced intensity-conditioned allo-SCT.
Allogeneic transplantation for relapsed myeloma HW Auner et al has substantially reduced morbidity and mortality from CMV disease. 30, 31 Nonetheless, CMV seropositivity has remained a strong adverse risk factor for allo-SCT. 32 One possible explanation for this is that CMV seropositivity may increase the incidence of GVHD, a major cause of NRM. 32, 33 However, we did not observe a statistically significantly higher rate of either acute GVHD or chronic GVHD in CMV-seropositive transplants (data not shown). An alternative explanation for higher NRM in CMV-seropositive transplants might be that pre-emptive anti-CMV therapy, which usually consists of ganciclovir administered for several weeks, frequently causes neutropenia and opportunistic infections. 32 Furthermore, CMV seropositivity is associated with increased risk of invasive aspergillosis after allo-SCT. 34 It is therefore possible that the lower NRM in CMV double seronegative transplants that we observed in this study is, at least in part, due to a lower rate of fatal infections. As data on CMV reactivation and infectious complications are not regularly reported to the registry, we cannot comment on whether this was relevant in the patients included in this study.
A recent study by the Center for International Blood and Marrow Transplantation Research (CIBMTR) identified younger age and time from diagnosis to transplant of p2 years as the factors associated with improved survival in patients receiving RIC and MA allo-SCT up-front, and for relapsed MM. 28 In our study, high age and a higher number of prior autografts add to worse outcome, although we could not document a significant impact of the time from the first autograft to RIC allo-SCT as an independent prognostic factor. The CIBMTR investigation also identified sibling transplants as a factor associated with improved survival, whereas our study did not detect a significant difference in NRM, PFS or OS between transplants from siblings and other donors. This disparity may at least, in part, be explained by improved unrelated donor selection due to better HLA typing, as our study included patients transplanted between 1999 and 2008, whereas the CIBMTR investigation included patients transplanted between 1989 and 2005.
Gender-mismatched transplants were associated with better PFS in our study, but their effect on OS and NRM failed to reach statistical significance. A previous study on the effect of donor gender in HLA-identical sibling-donor hematopoietic SCT for MM showed that the best OS was achieved in female-to-female transplants, but that female-to-male transplants were associated with both higher NRM and a significantly lower relapse rate compared with all other groups. 35 These findings, together with our observations, indicate the possibility of a gender-specific graftversus-myeloma effect.
It is an important strength of this investigation that it included a large number of patients, and that transplants were performed at multiple centres of various sizes and in different countries, thus providing a realistic view of outcomes of RIC-allo-SCT in the relapsed setting outside clinical trials. It might be considered a limitation of this study that potentially relevant factors such as cytogenetic abnormalities, International Staging System, pretransplant lactate dehydrogenase levels or extramedullary disease could not be included in the analysis, as they are not regularly reported to the database. However, the prognostic value of cytogenetic abnormalities and the International Staging System has not been established for allo-SCT or the relapsed setting, and some studies indicate that allo-SCT could overcome the poor prognostic impact of abnormalities, like del(17p) and t(4;14). 11, [36] [37] [38] Furthermore, recent evidence for clonal competition with alternating dominance of tumour subclones during disease progression suggests that the presence of genetic features at diagnosis may not allow conclusions to be made about their presence or absence at a later time during the disease course. [39] [40] [41] The database also fails to provide stringent information about treatment with novel agents. However, given that patients transplanted in the years 2004-2008 had the same outcome as patients transplanted in 1999-2003 (Supplementary Table 1 ), novel treatment modalities are unlikely to have had a major impact.
The median OS of 24.7 months and PFS of 9.6 months that we observed for the entire study population are similar to those reported for patients receiving a second auto-SCT for relapsed disease after one prior autograft. [42] [43] [44] [45] Rates for OS, PFS and NRM that we found in this study are also in the range of those reported in recent years in smaller studies for MM patients undergoing RIC allo-SCT for disease relapse/progression. 17, 18, 21 They are, however, worse than those for patients undergoing upfront RIC allo-SCT, which is not unexpected, given the prolonged disease history and more extensive prior therapies. [4] [5] [6] [7] [8] [9] [10] [11] [12] Although the relatively high NRM that we observed has to be taken into consideration, the data presented in this manuscript show that CMV-seronegative patients who have a CMV-seronegative donor have a substantially reduced NRM that translates into an encouraging 5-year survival of 440%. Considering that almost half (44.6%) of the patients in this study had undergone two or more prior autografts, our findings provide support to the notion that RIC allo-SCT can be an effective treatment option for some heavily pretreated patients. However, in line with a recent International Working Group Consensus statement, new strategies to further improve outcomes of allo-SCT in MM patients should only be explored in prospective trials in selected groups of patients. 3 The results of this study suggest that CMV serostatus could be a key factor in defining suitable patients and donors.
